Details of the Drug Combinations

General Information of This Drug (ID: DME47TX)

Drug Name

RG7112 DME47TX

Synonyms

RO5045337; QBGKPEROWUKSBK-QPPIDDCLSA-N; 939981-39-2; UNII-Q8MI0X869M; Q8MI0X869M; RO-5045337; CHEMBL2386346; Ro 5045337; GTPL9599; SCHEMBL12704861; DTXSID60240182; MolPort-044-560-282; EX-A1686; s7030; ZINC96270381; BDBM50434287; AKOS027282701; CS-0330; HY-10959; RG7112 (RO5045337); [(4s,5r)-2-(4-t-butyl-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dimethylimidazol-1-yl]-[4-(3-methylsulfonylpropyl)piperazin-1-yl]methanone; Methanone, [(4S,5R)-4,5-bis(4-chlorophenyl)-2-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]

Indication

Disease Entry	ICD 11	Status	REF
Haematological malignancy	2B33.Y	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[2]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
RG7112 + Cytarabine	DCUQWBU	Cytarabine	Myelogenous Leukemia, Acute	[3]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00559533) A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
2	Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.
3	ClinicalTrials.gov (NCT01635296) A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia